Antibiotic developer's stock soars 23% thanks to positive study data
Paratek Pharmaceuticals, a Boston biotech company that has rapidly expanded its presence in the Philadelphia suburbs, saw its stock price soar by 23 percent Tuesday after posting positive results from late-stage testing of its lead new drug candidate.
The study showed omadacycline, its experimental oral and IV antibiotic, met all the clinical trial's primary and secondary endpoints in treating patients with community-acquired bacterial pneumonia.
Paratek's stock closed up 23 percent at $22.85 per…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Bacterial Pneumonia | Biotechnology | Clinical Trials | Health Management | Pneumonia | Study